FDA Accepts BLA for ENNUMO (PEGFILGRASTIM-PCCG) by Accord Biopharma
The FDA has accepted the Biologics License Application for ENNUMO, a pegylated form of filgrastim.
Published: July 13, 2026
Updated: July 13, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Supportive Care
Company: Accord Biopharma
Asset: ENUMMO
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Accord Biopharma
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the BLA for ENNUMO signifies a potential shift in the oncology supportive care landscape, introducing competition for existing G-CSF therapies. Portfolio teams must assess the implications for market positioning and competitive dynamics.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for FDA review and potential approval, as well as market entry strategies.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.